<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394888</url>
  </required_header>
  <id_info>
    <org_study_id>High Risk Hemangioma</org_study_id>
    <nct_id>NCT00394888</nct_id>
  </id_info>
  <brief_title>Hemangioma Associated With High Rates of Morbidity</brief_title>
  <official_title>Hemangioma Associated With High Rates of Morbidity:A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State University of New York - Downstate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are conducting a study on the possible presence of PHACES in children with large facial
      hemangiomas and lumbosacral hemangiomas of infancy (hemangioma in the lower back) . With this
      study we hope to better understand the risk of this syndrome and to develop guidelines for
      its evaluation and management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large hemangiomas of the face can be associated with anomalies of the blood vessels of head
      and chest. The acronym PHACES indicates the association of Posterior fossa and other brain
      malformations, facial Hemangioma, Arterial anomalies, Coarctation of the aorta and other
      cardiac defects, Eye abnormalities and Sternal malformations. Study subjects will be
      recruited through the Pediatric Dermatology department in several cities. All patients age
      0-1 year old of age, who present with large facial hemangioma (&gt;22 cm^2) will be offered to
      participate in the study. Parents will be interviewed to obtain personal, medical, and family
      history.

      Patients will undergo standard of care evaluation for facial hemangioma with risk of PHACE
      syndrome. This includes skin, eye and neurological examination, photograph, magnetic
      resonance imaging (MRI) of head/neck/chest, and lab tests requiring samples of blood, urine
      or stool. No other tests will be performed for participating in the study.

      Lumbosacral hemangiomas of infancy (hemangioma in the lower back) can be associated with
      anomalies of the spine. &quot;Tethered cord syndrome&quot; indicates a condition caused by abnormally
      stretched spinal cord. Over time this condition can lead to neurological damage. Although
      often there are no symptoms until adulthood, it can become apparent during childhood. Common
      symptoms are: lower back pain, pain and weakness of the legs, walking problems, and bladder
      and bowel loss of control. &quot;Occult spinal dysraphism&quot; is the term used when the defect of the
      spine is hidden under normal skin. We noticed that infants with hemangioma in the lower back
      area are more inclined to present a hidden spine defect.

      Study subjects will be recruited through the Pediatric Dermatology departments in several
      cities. All patients age 0-18 year old of age, who present with lumbosacral hemangioma (&gt; 2.5
      cm of diameter overlying the spine) will be offered to participate in the study. Parents will
      be interviewed to obtain personal, medical, and family history.

      Patients will undergo standard of care evaluation for lumbosacral hemangioma. This includes
      skin, neurological examination, photograph, magnetic resonance imaging (MRI) of the back, lab
      tests requiring samples of blood, urine or stool. No additional tests will be performed only
      for participating in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI/MRA of Head/Neck/Chest.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Diagnosis of PHACE Syndrome</measure>
    <time_frame>2 years</time_frame>
    <description>For subjects in the large facial hemangioma arm of the study, a clinical assessment by trained physicians was conducted to determine whether or not each subject met diagnostic criteria for PHACE syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spinal Abnormalities</measure>
    <time_frame>2 years</time_frame>
    <description>The number of lumbrosacral hemangioma subjects with confirmed spinal abnormalities detected via lumbrosacral MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrovascular and Structural Brain Abnormalities</measure>
    <time_frame>2 years</time_frame>
    <description>The number of PHACE subjects identified with cerebrovascular and/or structural brain abnormalities detected using MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Abnormalities Detected Via Clinical Examination</measure>
    <time_frame>2 years</time_frame>
    <description>The number of subjects with clinically definite PHACE syndrome who were identified as having cardiac abnormalities following clinical examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Hepatic Hemangiomas Detected Via Abdominal Ultrasound</measure>
    <time_frame>2 years</time_frame>
    <description>The number of participants with multiple (greater than or equal to 5) cutaneous infantile hemangiomas who were found to have hepatic hemangiomas via the us abdominal ultrasound.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">433</enrollment>
  <condition>Hemangioma</condition>
  <arm_group>
    <arm_group_label>Facial Hemangioma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with large facial hemangioma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lumbosacral Hemangioma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with lumbosacral hemangioma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Hemangiomas</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with multiple hemangiomas (&gt;5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI of the spine.</description>
    <arm_group_label>Lumbosacral Hemangioma</arm_group_label>
    <arm_group_label>Multiple Hemangiomas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI of head and neck</intervention_name>
    <description>MRI of head and C-spine</description>
    <arm_group_label>Facial Hemangioma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dermatological Examination</intervention_name>
    <description>Complete dermatological examination to identify and characterize nature of dermatological anomalies</description>
    <arm_group_label>Facial Hemangioma</arm_group_label>
    <arm_group_label>Lumbosacral Hemangioma</arm_group_label>
    <arm_group_label>Multiple Hemangiomas</arm_group_label>
    <other_name>Clinical dermatological examination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac examination</intervention_name>
    <description>Complete cardiac examination</description>
    <arm_group_label>Facial Hemangioma</arm_group_label>
    <other_name>Cardiovascular examination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abdominal ultrasound</intervention_name>
    <description>Abdominal ultrasound to detect hepatic hemangiomas</description>
    <arm_group_label>Multiple Hemangiomas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Segmental Facial Hemangioma

        Inclusion criteria:

          -  Infants less than 1 year of age

          -  Hemangiomas of the head /facial area measuring 22cm2 or greater.

        Exclusion criteria:

          -  Children greater than 1 year of age.

          -  Children with segmental hemangiomas present in locations other than the head.

          -  Children presenting with localized (focal) or indeterminate hemangiomas in any
             location.

          -  Children with other vascular tumors (such as tufted angioma, Kaposiform
             hemangioendothelioma, non-involuting congenital hemangioma or rapidly-involuting
             congenital hemangioma) or vascular malformations.

        Lumbosacral Hemangioma

        Inclusion criteria:

          -  Individuals less than 18 years of age.

          -  Hemangioma, hemangioma precursor, or definitive residual hemangioma larger then 2.5 cm
             in diameter, overlying the midline lumbar spine or sacral spine in which any portion
             of the hemangioma is located over the midline.

        Exclusion Criteria:

          -  Excluding perirectal hemangiomas that do not extend onto the sacral spine.

          -  Excluding perineal hemangiomas that do extend to overlay the sacral spine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth Drolet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Garzon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denise Metry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilona Frieden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie Powell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Sainte-Justine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Lucky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Glick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York - Downstate Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eulalia Baselga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anita Haggstrom, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Mancini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimberly Horii, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Drolet, MD</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2006</study_first_submitted>
  <study_first_submitted_qc>November 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2006</study_first_posted>
  <results_first_submitted>May 4, 2011</results_first_submitted>
  <results_first_submitted_qc>June 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2011</results_first_posted>
  <last_update_submitted>September 17, 2013</last_update_submitted>
  <last_update_submitted_qc>September 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Beth Drolet</investigator_full_name>
    <investigator_title>Professor and Vice Chair of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Hemangioma</keyword>
  <keyword>PHACE</keyword>
  <keyword>Lumbosacral hemangioma</keyword>
  <keyword>Occult Spinal Dysraphism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatologic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Facial Hemangioma</title>
          <description>Patients with large facial hemangioma.</description>
        </group>
        <group group_id="P2">
          <title>Lumbosacral Hemangioma</title>
          <description>Patients with lumbosacral hemangioma.</description>
        </group>
        <group group_id="P3">
          <title>Multiple Hemangiomas</title>
          <description>Patients with multiple hemangiomas</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Facial Hemangioma</title>
          <description>Patients with large facial hemangioma.</description>
        </group>
        <group group_id="B2">
          <title>Lumbosacral Hemangioma</title>
          <description>Patients with lumbosacral hemangioma.</description>
        </group>
        <group group_id="B3">
          <title>Multiple Hemangiomas</title>
          <description>Patients with multiple hemangiomas</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="201"/>
            <count group_id="B4" value="357"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" spread="1"/>
                    <measurement group_id="B2" value="0.5" spread="1"/>
                    <measurement group_id="B3" value="0.5" spread="1"/>
                    <measurement group_id="B4" value="0.5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MRI/MRA of Head/Neck/Chest.</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>entire population count for MRI/A</description>
          </group>
        </group_list>
        <measure>
          <title>MRI/MRA of Head/Neck/Chest.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Diagnosis of PHACE Syndrome</title>
        <description>For subjects in the large facial hemangioma arm of the study, a clinical assessment by trained physicians was conducted to determine whether or not each subject met diagnostic criteria for PHACE syndrome.</description>
        <time_frame>2 years</time_frame>
        <population>Subjects enrolled in the large facial hemangioma arm (n= 108) were analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>entire population count for MRI/A</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Diagnosis of PHACE Syndrome</title>
          <description>For subjects in the large facial hemangioma arm of the study, a clinical assessment by trained physicians was conducted to determine whether or not each subject met diagnostic criteria for PHACE syndrome.</description>
          <population>Subjects enrolled in the large facial hemangioma arm (n= 108) were analyzed for this outcome measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spinal Abnormalities</title>
        <description>The number of lumbrosacral hemangioma subjects with confirmed spinal abnormalities detected via lumbrosacral MRI.</description>
        <time_frame>2 years</time_frame>
        <population>Subjects enrolled in the lumbrosacral hemangioma arm (n= 48) were analyzed for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>entire population count for MRI/A</description>
          </group>
        </group_list>
        <measure>
          <title>Spinal Abnormalities</title>
          <description>The number of lumbrosacral hemangioma subjects with confirmed spinal abnormalities detected via lumbrosacral MRI.</description>
          <population>Subjects enrolled in the lumbrosacral hemangioma arm (n= 48) were analyzed for this outcome measure</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cerebrovascular and Structural Brain Abnormalities</title>
        <description>The number of PHACE subjects identified with cerebrovascular and/or structural brain abnormalities detected using MRI.</description>
        <time_frame>2 years</time_frame>
        <population>Subjects diagnosed with clinically definite PHACE syndrome, enrolled in the large facial hemangioma arm (n= 33) were analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>entire population count for MRI/A</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrovascular and Structural Brain Abnormalities</title>
          <description>The number of PHACE subjects identified with cerebrovascular and/or structural brain abnormalities detected using MRI.</description>
          <population>Subjects diagnosed with clinically definite PHACE syndrome, enrolled in the large facial hemangioma arm (n= 33) were analyzed for this outcome measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Abnormalities Detected Via Clinical Examination</title>
        <description>The number of subjects with clinically definite PHACE syndrome who were identified as having cardiac abnormalities following clinical examination.</description>
        <time_frame>2 years</time_frame>
        <population>Subjects diagnosed with clinically definite PHACE syndrome, enrolled in the large facial hemangioma arm (n= 33) were analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>entire population count for MRI/A</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Abnormalities Detected Via Clinical Examination</title>
          <description>The number of subjects with clinically definite PHACE syndrome who were identified as having cardiac abnormalities following clinical examination.</description>
          <population>Subjects diagnosed with clinically definite PHACE syndrome, enrolled in the large facial hemangioma arm (n= 33) were analyzed for this outcome measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Hepatic Hemangiomas Detected Via Abdominal Ultrasound</title>
        <description>The number of participants with multiple (greater than or equal to 5) cutaneous infantile hemangiomas who were found to have hepatic hemangiomas via the us abdominal ultrasound.</description>
        <time_frame>2 years</time_frame>
        <population>Subjects enrolled in the hepatic hemangioma arm (n= 151) were analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>entire population count for MRI/A</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Hepatic Hemangiomas Detected Via Abdominal Ultrasound</title>
          <description>The number of participants with multiple (greater than or equal to 5) cutaneous infantile hemangiomas who were found to have hepatic hemangiomas via the us abdominal ultrasound.</description>
          <population>Subjects enrolled in the hepatic hemangioma arm (n= 151) were analyzed for this outcome measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Facial Hemangioma</title>
          <description>Patients with large facial hemangioma.</description>
        </group>
        <group group_id="E2">
          <title>Lumbosacral Hemangioma</title>
          <description>Patients with lumbosacral hemangioma.</description>
        </group>
        <group group_id="E3">
          <title>Multiple Hemangiomas</title>
          <description>Patients with multiple hemangiomas</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Beth Drolet</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>414-266-1569</phone>
      <email>bdrolet@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

